Disease or Syndrome – Page 102

BMS-Cellares Collaboration Spotlights U.S.-China Biopharma Rivalry

1 year ago talkbio0Tagged Biopharma, Burning Mouth Syndrome, Cancer Therapeutic Procedure, CAR-T, Cell Therapy, Cellares, Collaboration, rivalry, Tension, U.S.-China

BMS, Cellares, CAR-T, collaboration, U.S.-China tensions, biopharma rivalry, cell therapy, cancer treatment.

BenevolentAI Downsizes Operations, Cuts 30% of Workforce Amidst Funding Challenges

1 year ago talkbio0Tagged AI, Artificial Intelligence, BenevolentAI, Drug Discovery, GTPase-Activating Proteins, research

BenevolentAI, layoffs, workforce reduction, funding gap, US site closure, AI research, drug discovery

Incyte Invests in Mast Cell Inhibitors with $750M Escient Acquisition

1 year ago talkbio0Tagged Acquisition (action), Dosage Forms, Drug Development, Escient, Fibrosis, Incyte, Inflammatory disorder, mast cell inhibitors

Incyte, Escient, mast cell inhibitors, acquisition, pharmaceutical, drug development, inflammatory diseases, cancer, fibrosis, $750 million

FDA Issues Complete Response Letter to Abeona’s Cell Therapy for Rare Skin Disease

1 year ago talkbio0Tagged Abeona, Cell Therapy, Complete, CRL, Dermatologic disorders, Epidermolysis Bullosa, Infrequent, United States Food and Drug Administration

FDA, Complete Response Letter (CRL), Abeona, cell therapy, rare skin disease, Epidermolysis Bullosa (EB)

Boehringer Ingelheim and Ochre Bio Join Forces in a $1 Billion Collaboration to Combat Chronic Liver Diseases

1 year ago1 year ago talkbio0Tagged boehringer ingelheim, Chronic liver disease, Collaboration, Drug Discovery, Fibrosis, Liver, Nonalcoholic Steatohepatitis, RNA

Boehringer Ingelheim, Ochre Bio, collaboration, chronic liver diseases, $1 billion, drug discovery, RNA therapeutics, liver fibrosis, non-alcoholic steatohepatitis (NASH)

BMS Expands CAR-T Therapy Capabilities with Strategic $380 Million Investment in Cellares

1 year ago talkbio0Tagged Automation, Biotechnology, Burning Mouth Syndrome, Cancer Therapeutic Procedure, Capacity, CAR-T, Cell Therapy, Cellares, expansion, Investments, Manufacture, squibb

BMS, Bristol Myers Squibb, Cellares, CAR-T therapy, cell therapy, cancer treatment, biotechnology, investment, capacity expansion, manufacturing, automation.

Eli Lilly Anticipates Zepbound Label Expansion Following Positive Phase III Sleep Apnea Study Results

1 year ago talkbio0Tagged Eli, Eli Lilly, expansion, Identifier, Improvement, Phase III Sleep Apnea Study, Sleep Apnea, Obstructive, SURMOUNT-OSA, Symptoms, Zepbound

Eli Lilly, Zepbound (tirzepatide), Phase III Sleep Apnea Study, SURMOUNT-OSA, Obstructive Sleep Apnea (OSA), Label Expansion, Fast Track Designation, Symptom Improvement